BioVascular is Drug Discovery in United States that focus on significant unmet business. Founded in 2005. They cover business area such as developer, drug, device, novel cardiovascular therapeutic, significant unmet medical need, intimal hyperplasia, vascular procedure, control factor, cardiovascular morbidity, mortality, saratin, either hemodialysis access graft, peripheral bypass grafting, medical clinic, prevention, vascular disease.
2005
( 19 years old in 2024 )
Significant Unmet
-
12230 El Camino Real
Suite 100
San Diego, CA 92130
United States
Private
developerdrugdevicenovel cardiovascular therapeuticsignificant unmet medical needintimal hyperplasiavascular procedurecontrol factorcardiovascular morbiditymortalitysaratineither hemodialysis access graftperipheral bypass graftingmedical clinicpreventionvascular disease
* We use standard office opening hours in near BioVascular's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
BioVascular is Drug Discovery business from United States that founded in 2005 (19 years old in 2024), BioVascular business is focusing on Significant Unmet.
BioVascular headquarter office and corporate office address is located in 12230 El Camino Real Suite 100 San Diego, CA 92130 United States.
BioVascular was founded in United States.
In 2024, BioVascular is currently focus on significant unmet sector.
Above is snippet of Google Trends for "significant unmet" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with BioVascular, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
